India's Panacea Biotec begins producing Russia's Sputnik V vaccine -RDIF

Panacea Biotec

24/05/2021 10:30

MOSCOW, May 24 (Reuters) - Indian biotech firm Panacea
Biotec Ltd  PNCA.NS  on Monday began production of Russia's
Sputnik V vaccine against COVID-19, said the Russian Direct
Investment Fund (RDIF), which markets the shot internationally.
    The first batch made by the Indian manufacturer will be
shipped to Gamaleya, the Moscow institute which developed the
vaccine, for quality controls, RDIF said in a statement.
    Full-scale production is expected to begin this summer, RDIF
added. Panacea Biotec plans to produce 100 million doses of
Sputnik V annually, RDIF said in April.  urn:newsml:reuters.com:*:nR4N2L500B

 (Reporting by Anton Kolodyazhnyy; writing by Polina Ivanova;
editing by Jason Neely)
 ((p.ivanova@thomsonreuters.com;))